Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)

Organon

Status and phase: Completed; Phase 4

Conditions: Renal Disorder

Treatments: Drug: Comparator: amlodipine / Duration of Treatment: 20 weeks; Drug: MK0954, losartan potassium/Duration of Treatment: 20 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00140985

2005_058

MK0954-213

0954-213

Details and patient eligibility

About

Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.

Enrollment: 97 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Males or females at least 18 years of age with non-diabetic proteinuric renal diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind